Comparative Pharmacology
Head-to-head clinical analysis: DALBAVANCIN HYDROCHLORIDE versus VANCOCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALBAVANCIN HYDROCHLORIDE versus VANCOCIN HYDROCHLORIDE.
DALBAVANCIN HYDROCHLORIDE vs VANCOCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalbavancin inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing transglycosylation and transpeptidation. It is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive bacteria.
Vancomycin inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursor units, thereby preventing polymerization and cross-linking of peptidoglycan.
1500 mg intravenously as a single dose, or 1000 mg intravenously followed by 500 mg intravenously one week later.
15-20 mg/kg IV every 8-12 hours; maximum single dose 2 g. Target trough 10-20 mcg/mL.
None Documented
None Documented
Terminal elimination half-life of 14.4 days (range 8.5–16.0 days), permitting once-weekly dosing.
Terminal elimination half-life: 4-6 hours in adults with normal renal function; prolonged to 7-9 days in anuric patients, necessitating therapeutic drug monitoring.
Primarily renal excretion of unchanged drug (33%) and its active metabolite (12%), with additional biliary/fecal elimination (approximately 20% in feces).
Primarily renal (glomerular filtration): 80-90% of dose excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Category A/B
Category C
Glycopeptide Antibiotic
Glycopeptide Antibiotic